MedDataX Logo

Effects of Xal-Ease on Patient Compliance With Xalatan

NCT ID: NCT00573638

Last Updated: 2008-08-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-02-28

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

glaucoma compliance eye drops deliver aid Patients could range anywhere from 40 to 80 years old Patients must have diagnosis requiring treatment with Xalatan. Patients will be male or female and from any racial/ethnic background.

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xal-Ease device to be used with Xalatan eye drops

This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 40 to 80 years old
* Diagnosis warranting treatment with Xalatan eye drops.
* ambulatory and well functioning

Exclusion Criteria

* non-ambulatory
* less than 40 or greater than 80 years old
* Not using Xalatan eye drops
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role collaborator

Augusta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Medical College of Georgia

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christian D. Nilson, MD

Role: PRINCIPAL_INVESTIGATOR

Augusta University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical College of Georgia Health Inc

Augusta, Georgia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christian D. Nilson, MD

Role: CONTACT

Phone: 706-721-1150

Email: [email protected]

Sandra M. Johnson, MD

Role: CONTACT

Phone: 706-721-1150

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Guarantor or CPI # 002533552

Identifier Type: -

Identifier Source: secondary_id

05-02-266

Identifier Type: -

Identifier Source: org_study_id